Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study

Laprise, Jean-François; Drolet, Mélanie; Boily, Marie‐Claude; Jit, Mark; Sauvageau, Chantal; Franco, Eduardo L.; Lemieux-Mellouki, Philippe; Malagón, Talía; Brisson, Marc

doi:10.1016/j.vaccine.2014.07.099

Cited by 55 publications

(40 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccine safety and efficacy have been confirmed in pre- and post-licensure studies [11,12,14]. Fewer than the currently recommended three doses of HPV vaccines has been proven to be effective [15,16]. A switch from a three- to a two-dose schedule for primary immunization programmes is hence anticipated, especially in younger adolescents aged between 9 and 13 years [10].…”

Section: Primary Prevention Through Hpv Vaccinationmentioning

confidence: 99%

Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none

El‐Zein

Richardson

Franco

2016

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

Cervical cancer control includes primary prevention through vaccination to prevent human papillomavirus (HPV) infection and secondary prevention through screening to detect and treat cervical precancerous lesions. This review summarizes the evidence for the population impact of vaccines against oncogenic HPV types in reducing the prevalence of cervical precancerous lesions. We examine the gradual shift in screening technology from cervical cytology alone to cytology and HPV cotesting, and finally to the recognition that HPV testing can serve alone as the new screening paradigm, particularly in the initial post-vaccination era. We should expect an impact on screening performance and practices, as cohorts of HPV-vaccinated girls and adolescents reach cervical cancer screening age. In preparation for changes in the screening paradigm for the vaccination era, we propose that policymaking on cervical cancer screening should mirror current practices with other cancers as benchmarks. Cervical precancerous lesions will become a very rare condition following the widespread implementation of HPV vaccines with broader coverage in the number of preventable oncogenic types. Irrespective of screening technology, the false positive results will far outnumber the true positive ones, a tipping point that will herald a new period when the harms from cervical cancer screening will outweigh its benefits. We present a conceptual framework to guide decision making when we reach this point within 25–30 years.

show abstract

Section: Primary Prevention Through Hpv Vaccinationmentioning

confidence: 99%

Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none

El‐Zein

Richardson

Franco

2016

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…To systematically select them, we did a literature search on the international database PubMed (period 2010-2014; search terms 'HPV vaccine', 'cost-effectiveness' and 'two doses' or 'nonavalent'). We found three articles [13,18,19] [14] Laprise (2014) [19] Drolet (2013) [20] Journal ( and screened them to assess the main features we considered interesting from our viewpoint (TABLE 1).…”

Section: The Latest Modelsmentioning

confidence: 99%

“…Two compared the twoand three-dose schedules in Canada [18] and the UK [13], the third the nonavalent to the quadrivalent still in the first setting [19]. Two authors co-signed all three studies and four two of them.…”

Section: The Latest Modelsmentioning

confidence: 99%

Long-term modeling on HPV vaccination: do we really need any more?

Garattini

Curto

Vooren

2015

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

“…However, the prices of the vaccines vary significantly by region, from as little as $5 to as much as $187 per dose [12]. Recent studies suggest that two doses of vaccine may provide protective immunity [13,14] and be more cost-effective than the three-dose series [15]. However, cost remains the biggest barrier to national implementation of the HPV vaccine in LMICs [16].…”

Section: Introductionmentioning

confidence: 99%

A paper-based immunoassay to determine HPV vaccination status at the point-of-care

Grant

Smith

Castle

et al. 2016

Vaccine

View full text Add to dashboard Cite

Objective To develop and evaluate a paper-based point-of-care HPV serology test to determine if an individual has received two or more HPV immunizations. Methods The paper-based immunoassay was constructed using a nitrocellulose lateral flow strip with adsorbed HPV16 virus-like particles serving as the capturing moiety. Three capture zones containing virus-like particles were placed in series to allow for visual discrimination between high and low HPV16 plasma antibody concentrations. A plasma separation membrane was used to allow whole blood to be applied directly to the assay. All reagents were dried on glass fiber pads during device fabrication and were rehydrated with buffer at the time of use. A pilot study consisting of 35 subjects with a history of zero, one, two or three HPV vaccines was conducted to evaluate the immunoassay. The completed paper-based immunoassays were scanned for visual interpretation by three researchers who were blinded to the true results and separately evaluated quantitatively using MATLAB. Results For the 28 tests valid for analysis, fifteen subjects reported receiving two or more HPV vaccines, three reported receiving one, and ten reported having no HPV vaccinations. The paper-based immunoassays for all fifteen subjects who reported having received two or more HPV vaccines were judged positive by all researchers. Twelve of the thirteen tests from individuals reporting one or zero vaccinations were deemed negative by all observers. One test from an unvaccinated individual was judged positive by two out of three reviewers. Quantitatively, all tests were correctly separated between the two groups. Conclusions We successfully designed and tested a HPV serology test amenable to the point-of-care. The device showed promising results in a pilot study for discriminating between those who received two or more HPV vaccinations and those who did not. Furthermore, this device offers a platform for producing other semi-quantitative point-of-care serological tests.

show abstract

Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study

Cited by 55 publications

References 49 publications

Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none

Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none

Long-term modeling on HPV vaccination: do we really need any more?

A paper-based immunoassay to determine HPV vaccination status at the point-of-care

Contact Info

Product

Resources

About